Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
71 hedge funds and large institutions have $151M invested in Insys Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 3 closing their positions.
1,100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 3
214% more capital invested
Capital invested by funds: $48.1M → $151M (+$103M)
87% more funds holding
Funds holding: 38 → 71 (+33)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$10M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$6.41M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$6.09M |
| 4 |
Renaissance Technologies
New York
|
+$3.88M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$3.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$6.12M |
| 2 |
JP Morgan Chase
New York
|
-$5.54M |
| 3 |
RA
Royce & Associates
New York
|
-$5.02M |
| 4 |
BC
Broadfin Capital
New York
|
-$4.15M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.15M |
INSY Hedge Fund Activity: Q3 2013 in Review
71 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2013, worth a combined $151M — up 214% from $48.1M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new INSY positions and 3 closed out — a net gain of 33 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $10M. The largest seller was Putnam Investments, cutting an estimated $6.12M.
- 71 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2013, up from 38 in Q2 2013.
- Funds reported $151M of Insys Therapeutics, Inc. stock for Q3 2013, up 214% quarter-over-quarter.
- 36 funds opened new Insys Therapeutics, Inc. positions in Q3 2013 and 3 closed out, a net change of +33 holders.
- The largest Insys Therapeutics, Inc. buyer in Q3 2013 was Consonance Capital Management, an estimated $10M added.
- The largest Insys Therapeutics, Inc. seller in Q3 2013 was Putnam Investments, an estimated $6.12M sold.
Based on aggregated 13F filings for Q3 2013.